类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响

doi:10.11904/j.issn.1002-3070.2019.05.016

摘要/Abstract

摘要： 类固醇激素尤其雌激素和孕激素在乳腺癌的发病、进展和治疗中起着重要作用。与此同时,大量的研究证实肿瘤干细胞在乳腺癌发生、进展和转移过程中也起着关键作用。在乳腺癌临床治疗中,尽管肿瘤细胞经过常规抗内分泌治疗后受到了明显的抑制,但仅需少量的乳腺肿瘤干细胞(Breast cancer stem cells,BCSCs)存在,仍可维持肿瘤的再生长。以往大量的研究多集中在激素对正常乳腺发育及其与乳腺癌的相关性方面,最近,更多的研究观察激素对乳腺肿瘤干细胞活性影响,这为乳腺癌治疗和肿瘤干细胞研究开辟了新的方向。本文全面讨论类固醇激素(雌激素和孕激素)在乳腺癌中的作用及其对乳腺肿瘤干细胞的活性调节。

关键词: 乳腺癌, 肿瘤干细胞, 雌激素, 孕激素

Abstract: Steroid hormones,especially estrogens and progestins,play an important role in the pathogenesis,progression and treatment of breast cancer.At the same time,a large number of studies have confirmed that cancer stem cells also play a key role in the occurrence,progression and metastasis of breast cancer.In preclinical models of breast cancer,although tumor cells have been significantly inhibited by conventional anti-endocrine therapy,only a small number of breast cancer stem cells(BCSCs)are needed to maintain tumor re-growth.In the past,a large number of studies have focused on the relationship between hormones in the development of normal breast and breast cancer.Recently,many studies have examined effects of hormones on the activity of breast cancer stem cell,which has opened up a new research direction for breast cancer treatment and CSCs.This paper comprehensively discusses the role of steroid hormones(estrogen and progesterone)in breast cancer and their regulation of breast BCSCs.

Key words: Breast cancer, Cancer stem cells, Estrogen, Progesterone

中图分类号:

R730.43

王宇, 乔娟娟, 张磊, 刘四卫 , 杨树才. 类固醇激素在乳腺癌中的作用及对肿瘤干细胞的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 466-470.

WANG Yu, QIAO Juanjuan, ZHANG Lei, LIU Siwei, YANG Shucai. The role of steroid hormones in breast cancer and its effect on cancer stem cells[J]. Journal of Practical Oncology, 2019, 33(5): 466-470.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2019.05.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2019/V33/I5/466

参考文献

1 Collina F,Bonito MD,Bergolis VL,et al.Prognostic value of cancer stem cells markers in triple-negative breast cancer[J].Biomed Res Int,2016,2015(4):1-10.
2 陈明慧,陈喜杰,王艳.CD44v6与非小细胞肺癌的研究进展[J].实用肿瘤学杂志,2016,30(2):172-175.
3 Basakran NS.CD44 as a potential diagnostic tumor marker[J].Saudi Med J,2015,36(3):273-279.
4 Charafe-Jauffret E,Ginestier C,Iovino F,et al.Aldehyde dehydrogenase1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer[J].Clin Cancer Res,2010,16(1):45-55.
5 Liu S,Cong Y,Wang D,et al.Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts[J].Stem Cell Reports,2014,2(1):78-91.
6 Arendt LM,Kuperwasser C.Form and function:how estrogen and progesterone regulate the mammary epithelial hierarchy[J].J Mammary Gland Biol Neoplasia,2015,20(1/2):9-25.
7 Carroll JS,Liu XS,Brodsky AS,et al.Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1[J].Cell,2005,122(1):33-43.
8 Clemons M,Goss P.Estrogen and the risk of breast cancer[J].N Engl J Med,2001,344(4):276-285.
9 Simoes BM,O'Brien CS,Eyre R,et al.Anti-estrogen resistance in human breast tumors is driven by JAG1-NOTCH4-dependent cancer stem cell activity[J].Cell Rep,2015,12(12):1968-1977.
10 Huang ZJ,You J,Luo WY,et al.Reduced tumorigenicity and drug resistance through the downregulation of octamer-binding protein 4 and Nanog transcriptional factor expression in human breast stem cells[J].Mol Med Rep,2015,11(3):1647-1654.
11 Kurebayashi J,Kanomata N,Yamashita T,et al.Antitumor and anticancer stem cell activities of eribulin mesylate and antiestrogens in breast cancer cells[J].Breast,2015,24(3):425-436.
12 Axlund SD,Yoo BH,Rosen RB,et al.Progesterone-inducible cytokeratin 5-positive cells in luminal breast cancer exhibit progenitor properties[J].Horm Cancer,2013,4(1):36-49.
13 Zhou X,Wang S,Wang Z,et al.Estrogen regulates Hippo signaling via GPER in breast cancer[J].J Clin Invest,2015,125(5):2123-2135.
14 Cordenonsi M,Zanconato F,Azzolin L,et al.The hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells[J].Cell,2011,147(4):759-772.
15 Amabile M,De Smet R,Moriconi C,et al.TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells[J].Oncogene,2014,34(6):681-690.
16 Deng H,Zhang XT,Wang ML,et al.ER-alpha36-mediated rapid estrogen signaling positively regulates ER-positive breast cancer stem/progenitor cells[J].PLoS One,2014,9(2):e88034.
17 Gelsomino L,Panza S,Giordano C,et al.Mutations in the estrogen receptor alpha hormone binding domain promote stem cell phenotype through Notch activation in breast cancer cell lines[J].Cancer Lett,2018,428:12-20.
18 Deng H,Yin L,Zhang XT,et al.ER-alpha variant ER-alpha36 mediates antiestrogen resistance in ER-positive breast cancer stem/progenitor cells[J].J Steroid Biochem Mol Biol,2014,144:417-426.
19 Kang L,Guo Y,Zhang X,et al.A positive cross-regulation of HER2 and ER-alpha36 controls ALDH1 positive breast cancer cells[J].J Steroid Biochem Mol Biol,2011,127(3-5):262-268.
20 Ma R,Karthik GM,John Lövrot J,et al.Estrogen receptor β as a therapeutic target in breast cancer stem cells[J].J Natl Cancer Inst,2017,109(3):1-14.
21 Lawson DA,Bhakta NR,Kessenbrock K,et al.Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells[J].Nature,2015,526(7571):131-135.
22 Jameera BA,Jubie S,Nanjan MJ.Estrogen receptor agonists/antagonists in breast cancer therapy:A critical review[J].Bioorg Chem,2017,71:257-274.
23 Creighton CJ,Li X,Landis M,et al.Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features[J].Proc Natl Acad Sci U S A,2009,106(33):13820-13825.
24 Shea MP,O′Leary KA,Fakhraldeen SA,et al.Anti-estrogen therapy increases plasticity and cancer stemness of prolactin-induced ERα+ mammary carcinomas[J].Cancer Res,2018,78(7):1672-1684.
25 Sansone P,Berishaj M,Rajasekhar VK,et al.Evolution of cancer stem-like cells in endocrine-resistant metastatic breast cancers is mediated by stromal microvesicles[J].Cancer Res,2017,77(19):5438.
26 Carlini MJ,Recouvreux MS,Simian M,et al.Gene expression profile and cancer-associated pathways linked to progesterone receptor isoform a(PRA)predominance in transgenic mouse mammary glands[J].BMC Cancer,2018,18(1):682.
27 Boonyaratanakornkit V,Hamilton N,MárquezGarbán DC,et al.Extranuclear signaling by sex steroid receptors and clinical implications in breast cancer[J].Mol Cell Endocrinol,2017,466:51-72.
28 Joshi PA,Jackson HW,Beristain AG,et al.Progesterone induces adult mammary stem cell expansion[J].Nature,2010,465(7299):803-807.
29 Goyette S,Liang Y,Mafuvadze B,et al.Natural and synthetic progestins enrich cancer stem cell-like cells in hormone-responsive human breast cancer cell populations in vitro[J].Breast Cancer,2017,9:347-357.
30 Schramek D,Leibbrandt A,Sigl V,et al.Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer[J].Nature,2010,468(7320):98-102.
31 Beral V,Reeves G,Bull D,et al.Breast cancer risk in relation to the interval between menopause and starting hormone therapy[J].J Natl Cancer Inst,2011,22(4):360-362.
32 Wood CE,Branstetter D,Jacob AP,et al.Progestin effects on cell proliferation pathways in the postmenopausal mammary gland.Breast Cancer Res[J].2013,15(4):62.
33 Azam S,Lange T,Huynh S,et al.Hormone replacement therapy,mammographic density,and breast cancer risk:a cohort study[J].Cancer Causes Control,2018,29(6):495-505.
34 Fettig LM,Mcginn O,Finlayschultz J,et al.Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells[J].Oncogene,2017,36(44):6074-6084.
35 Howe EN.Progestin suppression of miR-29 potentiates dedifferentiation of breast cancer cells via KLF4[J].Oncogene,2013,32(20):2555-2564.
36 Shiah YJ,Tharmapalan P,Casey AE,et al.A progesterone-CXCR4 axis controls mammary progenitor cell fate in the adult gland[J].Stem Cell Reports,2015,4(3):313-322.
37 Finlay-Schultz J,Cittelly DM,Hendricks P,et al.Progesterone downregulation of miR-141 contributes to expansion of stem-like breast cancer cells through maintenance of progesterone receptor and STAT5a[J].Oncogene,2015,34(28):3676-3687.
38 Zhang P,Andrianakos R,Yang Y,et al.Kruppel-like factor 4(Klf4)prevents embryonic stem(ES)cell differentiation by regulating Nanog gene expression[J].J Biol Chem,2010,285(12):9180-9189.
39 Reichenstein M,Rauner G,Kfir S,et al.Luminal STAT5 mediates H2AX promoter activity in distinct population of basal mammary epithelial cells[J].Oncotarget,2016,7(27):41781-41797.
40 Hurtz C,Hatzi K,Cerchietti L,et al.BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia[J].J Exp Med,2011,208(11):2163-2174.
41 Goodman CR,Sato T,Peck AR,et al.Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism[J].Oncogene,2016,35(11):1373-1385.
42 Alfakeeh A,Brezdenmasley C.Overcoming endocrine resistance in hormone receptor-positive breast cancer[J].Current Oncology,2018,25(Suppl 1):18.
43 Esber N,Cherbonnier C,Resche-Rigon M,et al.Anti-tumoral effects of anti-progestins in a patient-derived breast cancer xenograft model[J].Horm Cancer,2016,7(2):137-147.
44 Mohammed H,Russell IA,Stark R,et al.Progesterone receptor modulates ERalpha action in breast cancer[J].Nature,2015,523(7560):313-317.

[1]	师镘茹, 鄂明艳. 放疗延迟对乳腺癌不同分子亚型患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(5): 431-435.
[2]	李磊 , 张清媛. 乳腺癌抗肿瘤血管治疗的临床进展[J]. 实用肿瘤学杂志, 2019, 33(5): 461-465.
[3]	刘尔钰, 杨昊, 梁国华, 赵晏方, 赵文辉. CDK4/6抑制剂联合mTOR抑制剂在乳腺癌中的作用机制[J]. 实用肿瘤学杂志, 2019, 33(5): 476-480.
[4]	安巍巍, 唐雅莉, 赵莲花, 杨悦, 王新玲. 红松松塔提取物多聚苯丙素-多糖复合物诱导人乳腺癌MCF-7细胞凋亡[J]. 实用肿瘤学杂志, 2019, 33(4): 289-293.
[5]	胡琳, 沈佳. GDF-15在预测和监控表柔比星/环磷酰胺-多西他赛-曲妥珠单抗辅助治疗HER-2阳性乳腺癌患者产生心脏毒性中的作用[J]. 实用肿瘤学杂志, 2019, 33(4): 340-345.
[6]	马焱, 何红, 王赛男. 多西他赛解救治疗不同年龄组转移性乳腺癌的临床研究[J]. 实用肿瘤学杂志, 2019, 33(4): 352-356.
[7]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[8]	王晓雅,肖斌,廖扬,唐荣芝,孙朝晖,李林海. CXCR家族蛋白在不同乳腺癌亚型中的表达及临床预后分析[J]. 实用肿瘤学杂志, 2019, 33(3): 206-210.
[9]	李烁,张楠楠,李亮亮,龙志平,尹慧慧,赵亚双,王帆. 外周血白细胞PDE4C基因甲基化及环境因素交互作用与乳腺癌发病的关系[J]. 实用肿瘤学杂志, 2019, 33(3): 233-238.
[10]	李嘉琪,栾瑾微,张,玉,李香兰. 763例三阴性乳腺癌临床病理特征及复发、转移影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(3): 244-249.
[11]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[12]	陈艳波, 孔德嘉, 张金锋, 马志刚. 乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究[J]. 实用肿瘤学杂志, 2019, 33(2): 110-114.
[13]	孙江宏, 郝明珠, 姜丹, 国飞, 李晓梅. 乳腺炎、良性增生及乳腺癌FFDM鉴别诊断思路[J]. 实用肿瘤学杂志, 2019, 33(2): 139-141.
[14]	马志杰, 王帆, 赵亚双. 乳腺癌化疗患者生存质量及影响因素分析[J]. 实用肿瘤学杂志, 2019, 33(2): 149-154.
[15]	马质莹, 尚乃舰, 蔡妙田, 沈阳, 姜智允. 孕激素及雌激素受体阳性乳腺癌HER-2受体与钼靶影像学特征及临床病理学特征的相关性分析[J]. 实用肿瘤学杂志, 2019, 33(1): 47-51.